Document is current

Article History

Received: 12 July 2024

Accepted: 25 December 2024

First Online: 8 January 2025

Declarations

:

: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the ethics committee of University Medicine Greifswald (Identifier: BB 034/19a, 2nd March 2021). Written informed consent has been obtained from all patients included in this study for data collection and the use of personal records for research.

: Not applicable.

: Erich-Franz Solomayer declares financial and non-financial competing interests in cooperation with pharmaceutic companies (Amgen, Astra Zeneca, Celgene, Clovis Oncology, Eisai, Erbe, Gedeon Richter, Genomic Health, GSK, Jenapharm, Johnson Johnson, Medac, Mentor, Novartis, Pfizer, Pierre Fabre, Pharma Mar, MSD, Roche, Roche-Posay, Samsung, Storz, Teva, Vifor) and in memberships or leading position in interest groups (German-Romanian Society of the DGGG, German-Hungarian Society of the DGGG, Association of Saarland Surgeons, DGGG, DEGUM (German Society for Ultrasound in Medicine), AGUB (Working Group for Urogynecology of the DGGG), DGS (German Society for Senology), AGO (Working Group for Gynecological Oncology), German Continence Society, DOG (German Society for Osteooncology), German University Association, ARC Gynecology, Saarland Cancer Society, AGE, German Cancer Society, Endometriosis Research Foundation, European Endometriosis League, Association of Friends of the UKS, Working Group for AGCPC, BLFG, Breast Organ Commission of the AGO, AWMF, Saarland Tumor Center at the UKS e.V., UKS/ UdS, ETC, ESGE, FOG, MedConcept, BVF). All other authors declare no competing interests.